Michal Maciej Nowicki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Michal Maciej Nowicki has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anna Latos-Bielenska
Department of Medical Genetics, Poznan University of Medical Sciences, 60-352 Poznan, Poland
1 shared publication - Anna Monies-Nowicka
Poznan University of Medical Sciences, Poznan, Poland
1 shared publication - Anna Winczewska-Wiktor
Department of Developmental Neurology, Poznan University of Medical Sciences, 60-355 Poznan, Poland
1 shared publication - Barbara Steinborn
Department of Developmental Neurology, Poznan University of Medical Sciences, 61-701 Poznan, Poland
1 shared publication - Dorota Monies
Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
1 shared publication - Magdalena Badura-Stronka
Department of Medical Genetics, Poznan University of Medical Sciences, 60-806 Poznan, Poland
1 shared publication
Latest Publications
- Open Access
- 12 March 2016
- Published by Springer Nature in BMC Neurology
- Vol. 16 (1) , 1-6
A de novo CTNNB1 nonsense mutation associated with syndromic atypical hyperekplexia, microcephaly and intellectual disability: a case report
In addition to its role in cell adhesion and gene expression in the canonical Wingless/integrated Wnt signaling pathway, β-catenin also regulates genes that underlie the transmission of nerve impulses. Mutations of CTNNB1 (β-catenin) have recently been described in patients with a wide range of neurodevelopmental disorders (intellectual disability, microcephaly and other syndromic features). We for the first time associate CTNNB1 mutation with hyperekplexia identifying it as an additional candidate for consideration in patients with startle syndrome. We describe an 11 year old male Polish patient with a de novo nonsense mutation in CTNNB1 who in addition to the major features of CTNNB1-related syndrome including intellectual disability and microcephaly, exhibited hyperekplexia and apraxia of upward gaze. The patient became symptomatic at the age of 20 months exhibiting delayed speech and psychomotor development. Social and emotional development was normal but mild hyperactivity was noted. Episodic falls when startled by noise or touch were observed from the age of 8.5 years, progressively increasing but never with loss of consciousness. Targeted gene panel next generation sequencing (NGS) and patient-parents trio analysis revealed a heterozygous de novo nonsense mutation in exon 3 of CTNNB1 identifying a novel association of β-catenin with hyperekplexia. We report for the first time a clear association of mutation in CTNNB1 with an atypical syndromic heperekplexia expanding the phenotype of CTNNB1-related syndrome. Consequently CTNNB1 should be added to the growing list of genes to be considered as a cause of startle disease or syndromic hyperekplexia.
- 12 March 2016
- Published by Springer Nature in BMC Neurology
- Vol. 16 (1) , 1-6
Open AccessA de novo CTNNB1 nonsense mutation associated with syndromic atypical hyperekplexia, microcephaly and intellectual disability: a case report
In addition to its role in cell adhesion and gene expression in the canonical Wingless/integrated Wnt signaling pathway, β-catenin also regulates genes that underlie the transmission of nerve impulses. Mutations of CTNNB1 (β-catenin) have recently been described in patients with a wide range of neurodevelopmental disorders (intellectual disability, microcephaly and other syndromic features). We for the first time associate CTNNB1 mutation with hyperekplexia identifying it as an additional candidate for consideration in patients with startle syndrome. We describe an 11 year old male Polish patient with a de novo nonsense mutation in CTNNB1 who in addition to the major features of CTNNB1-related syndrome including intellectual disability and microcephaly, exhibited hyperekplexia and apraxia of upward gaze. The patient became symptomatic at the age of 20 months exhibiting delayed speech and psychomotor development. Social and emotional development was normal but mild hyperactivity was noted. Episodic falls when startled by noise or touch were observed from the age of 8.5 years, progressively increasing but never with loss of consciousness. Targeted gene panel next generation sequencing (NGS) and patient-parents trio analysis revealed a heterozygous de novo nonsense mutation in exon 3 of CTNNB1 identifying a novel association of β-catenin with hyperekplexia. We report for the first time a clear association of mutation in CTNNB1 with an atypical syndromic heperekplexia expanding the phenotype of CTNNB1-related syndrome. Consequently CTNNB1 should be added to the growing list of genes to be considered as a cause of startle disease or syndromic hyperekplexia.